Myovant Sciences Ltd (NYSE:MYOV) Major Shareholder Sciences Ltd. Roivant Purchases 75,000 Shares

Myovant Sciences Ltd (NYSE:MYOV) major shareholder Sciences Ltd. Roivant acquired 75,000 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were acquired at an average price of $17.06 per share, for a total transaction of $1,279,500.00. Following the completion of the purchase, the insider now owns 44,623,079 shares of the company’s stock, valued at approximately $761,269,727.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Sciences Ltd. Roivant also recently made the following trade(s):

  • On Monday, December 2nd, Sciences Ltd. Roivant bought 179,193 shares of Myovant Sciences stock. The shares were purchased at an average cost of $18.44 per share, with a total value of $3,304,318.92.
  • On Monday, November 25th, Sciences Ltd. Roivant bought 3,500,000 shares of Myovant Sciences stock. The shares were purchased at an average cost of $15.00 per share, with a total value of $52,500,000.00.
  • On Wednesday, November 20th, Sciences Ltd. Roivant bought 121,906 shares of Myovant Sciences stock. The shares were purchased at an average cost of $12.90 per share, with a total value of $1,572,587.40.

Shares of NYSE MYOV traded down $1.30 during trading on Wednesday, hitting $17.32. The company had a trading volume of 3,799,900 shares, compared to its average volume of 777,728. The stock has a fifty day simple moving average of $8.74 and a two-hundred day simple moving average of $8.20. Myovant Sciences Ltd has a fifty-two week low of $4.14 and a fifty-two week high of $26.02. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -4.23 and a beta of 2.02. The company has a quick ratio of 2.79, a current ratio of 2.79 and a debt-to-equity ratio of 5.88.

Myovant Sciences (NYSE:MYOV) last announced its earnings results on Tuesday, November 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.07). On average, analysts anticipate that Myovant Sciences Ltd will post -3.29 earnings per share for the current year.

Several research analysts recently issued reports on the stock. Goldman Sachs Group reissued a “buy” rating and set a $20.00 target price (up previously from $18.00) on shares of Myovant Sciences in a report on Tuesday, November 19th. Zacks Investment Research cut shares of Myovant Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 9th. ValuEngine cut shares of Myovant Sciences from a “buy” rating to a “hold” rating in a report on Tuesday. Leerink Swann assumed coverage on shares of Myovant Sciences in a report on Monday, August 19th. They set an “outperform” rating and a $26.00 target price for the company. Finally, Cowen reissued a “buy” rating on shares of Myovant Sciences in a report on Tuesday, November 12th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $23.46.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its holdings in shares of Myovant Sciences by 46.3% in the 3rd quarter. Tower Research Capital LLC TRC now owns 9,741 shares of the company’s stock valued at $51,000 after buying an additional 3,083 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Myovant Sciences by 59.1% in the 2nd quarter. BlackRock Inc. now owns 44,637 shares of the company’s stock valued at $404,000 after purchasing an additional 16,580 shares in the last quarter. Virtus ETF Advisers LLC purchased a new position in shares of Myovant Sciences in the 2nd quarter valued at about $279,000. Morgan Stanley increased its holdings in shares of Myovant Sciences by 1,970.7% in the 2nd quarter. Morgan Stanley now owns 74,337 shares of the company’s stock valued at $673,000 after purchasing an additional 70,747 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Myovant Sciences by 34.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 112,361 shares of the company’s stock valued at $1,039,000 after purchasing an additional 28,941 shares in the last quarter. Institutional investors own 38.81% of the company’s stock.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Further Reading: How is a price target determined?

Insider Buying and Selling by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.